IMB Centre for Inflammation and Disease Research

Inflazome, a startup company developing treatments for inflammatory diseases based on a research partnership between The University of Queensland and Trinity College Dublin (TCD) has been acquired in a landmark deal by Roche.

Some new studies have found people who were never symptomatic, exposed to, or tested positive for COVID-19 that have immune cells that can recognise COVID-19.

Instead of protecting us from the virus that causes COVID-19, the body's natural defence mechanisms can overreact and inflict damage. Understanding why could make the infection far less dangerous.

A mission to reprogram innate immunity to combat inflammatory and infectious diseases has been supported by the National Health and Medical Research Council.

Nearly two million antibody tests imported into Australia are not much better than flipping a coin.

With much of society now effectively in lockdown, how will we know when it’s safe to resume something like normality?

Ian Henderson, Professor of Microbiology, and Dr Larisa Labzin, Virologist, discuss COVID-19 – immunity, vaccine development, epidemiology and what we do and don’t know.

Four IMB women will share how they are tackling big problems such as obesity and cardiovascular disease, stroke, spinal cord injuries and sheep parasites through the Queensland Women in STEM competition.

IMB researchers have helped identify a possible drug target for chronic liver disease.